IQ-AI Limited The Benefits and Significance of IB Neuro
24 9월 2020 - 6:43PM
RNS Non-Regulatory
TIDMIQAI
IQ-AI Limited
24 September 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
The benefits and significance of IB Neuro
IB Neuro, the flagship brand of IQ-AI's subsidiary Imaging
Biometrics ("IB"), was the first commercially available dynamic
susceptibility contrast ("DSC") perfusion approach and remains the
only platform that automatically generates quantitative output;
output that has been spatially validated with biopsy samples by
multiple groups and enables objective longitudinal monitoring of
treatment. In June of this year, Neuro Oncology published their
consensus recommendations for the DSC MRI protocol available in IB
Neuro(TM). This recommended protocol was the outcome of a large
subcommittee of the Jumpstarting Brain Tumour Drug Development
Coalition and provided evidence-based Best Practices for routine
clinical use.
Being the acknowledged standard in dynamic susceptibility
contrast imaging is a notable milestone. MR DSC is the most common
perfusion technology used for the evaluation of brain tumours, but
most sites have yet to adopt or have as yet fully comprehended the
value of having proven quantitative biomarkers available for brain
tumour assessment.
The post-processing of DSC data has evolved since the inception
of IB in 2007. Now fully automated, a full array of perfusion
parameter maps is generated within seconds. In addition,
exclusively licensed technology transforms the inherently variable
MR data to a fixed and known scale. This approach, demonstrated to
be superior to various tissue normalisation approaches, quantifies
output values across scanner vendors, field strengths, patients,
and timepoints and allows for longitudinal comparison. Moreover, IB
remains focused on advancing the field of MR DSC imaging, as
recently evidenced by receiving two major NIH grants. Together,
with an outstanding team of clinical and scientific collaborators,
IB is well-positioned to further its lead in brain tumour imaging
and treatment monitoring and apply those learnings to other cancers
and pathologies beyond the brain, setting new standards.
In the last 18 months, the team at IB has ported its core
processing libraries, including the DSC technology in IB Neuro, to
standalone software algorithms. Downloadable from IB, these
software solutions can be networked between any site's MRI
scanner(s) and PACS. Acquired datasets are processed and
automatically routed to the PACS for viewing and interpretation.
This automated processing is ideal for any-sized site as
volume-based pricing allows for affordable and immediate access for
any clinic. As previously announced, Keck Medical Centre of USC
acquired IB's approach for the automated generation of quantitative
parameter maps. Keck Medical Centre is one of 71 cancer centres
having obtained special designation by the US National Cancer
Institute (NCI), placing them in the top 4% of the approximately
1,500 cancer centres in the US. These centres provide cutting-edge
treatments to patients and are typically located in large
metropolitan cities across the USA.
On average, brain tumour patients will receive between 3 and 5
follow-up scans per year to monitor treatment. Thus, each site
performs several thousand neuro MRI exams annually, which
represents a tremendous opportunity for IB Neuro. Moreover, IB's
approach is not limited to NIH cancer centres in major metropolitan
cities. A tiered pricing structure makes it possible for any sized
institution to standardise its brain tumour imaging protocol.
The true value of IB Neuro's recommended DSC approach is in its
ability to quantify DSC perfusion imaging data regardless of where,
when, or on which scanner platform the data are acquired. This
means that patients could obtain their follow-up scans at any one
of the more than 6,000 hospitals or 7,000 imaging centres, have the
data processed by IB Neuro, and sent to their treatment team. Prior
datasets can be compared to the most current, and quantitatively
assessed to evaluate changes in tumour size, location, etc. It is a
convenience that brain tumour patients and their families deserve
and, more importantly, it is a proven biomarker that objectively
answers many questions faced by today's radiologists, oncologists,
and surgeons as they provide care for these patients.
As more clinicians become aware of the value of a standardised
DSC imaging protocol, IB anticipates that many other hospitals and
imaging centres will seek to utilise IB Neuro.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics , LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAFIFSAALISFII
(END) Dow Jones Newswires
September 24, 2020 05:43 ET (09:43 GMT)
Flying Brand (LSE:FBDU)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Flying Brand (LSE:FBDU)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024